ArticleBiomedical engineering letters2026
Measuring vancomycin using paired pulse voltammetry with a wireless instantaneous neurotransmitter concentration sensing system for point-of-care patient treatment.
Article in Biomedical engineering letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Vancomycin is a glycopeptide antibiotic widely used for severe Gram-positive infections, particularly methicillin-resistant Staphylococcus aureus (MRSA). However, its narrow therapeutic index necessitates precise monitoring to avoid nephrotoxicity, ototoxicity, or hematologic toxicity. Current therapeutic drug monitoring relies on serum assays requiring several hours, delaying timely dose adjustments. Electrochemical approaches such as fast-scan cyclic voltammetry (FSCV) offer potential for real-time bedside monitoring. We used bare AS4 carbon fiber microelectrodes (CFMs) as the vancomycin sensor. The Wireless Instantaneous Neurotransmitter Concentration Sensing (WINCS) Harmoni system, a portable and clinically compatible platform, was used to perform FSCV measurements of vancomycin. Waveform parameters were optimized, and paired-pulse voltammetry (PPV) was applied to enhance detection selectivity in vitro across varying vancomycin concentrations. Two distinct oxidation peaks of vancomycin were observed. PPV analysis indicated that the + 1.44 V peak is predominantly pH-independent, while the + 0.69 V peak demonstrates pH-dependent characteristics. Furthermore, the optimized FSCV waveform yielded a detection limit of 0.36 μM with stable and reproducible signal performance. Paired-pulse FSCV using the WINCS Harmoni platform enables sensitive, real-time electrochemical detection of vancomycin. This approach may support future rapid point-of care monitoring and inform individualized dosing strategies in critical care settings. Graphical abstract:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.